title: Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.
authors.affiliation: Augmentium Pharma Consulting, Toronto, Ontario, Canada. george@augmentium.com
authors.forename: George
authors.initials: G
authors.lastname: Dranitsaris
authors.forename: Susan R
authors.initials: SR
authors.lastname: Kahn
authors.forename: Carmine
authors.initials: C
authors.lastname: Stumpo
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Paton
authors.forename: Josee
authors.initials: J
authors.lastname: Martineau
authors.forename: Reginald
authors.initials: R
authors.lastname: Smith
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Ginsberg
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000145:classification / Q000191:economics* / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects / Q000191:economics; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects / Q000191:economics; D002170:Canada / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D017984:Enoxaparin / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D000077425:Fondaparinux; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006801:Humans; D017059:Models, Econometric; D019637:Orthopedic Procedures / Q000009:adverse effects; D011134:Polysaccharides / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012449:Safety; D013923:Thromboembolism / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D011134:Polysaccharides; D000077425:Fondaparinux